Enlivex Therapeutics Ltd
Change company Symbol lookup
Select an option...
ENLV Enlivex Therapeutics Ltd
HBUV Hubilu Venture Corporation
LMNL Liminal BioSciences Inc
NXTD NXT-ID Inc
RIOT Riot Blockchain Inc
HIHO Highway Holdings Ltd
CBAY Cymabay Therapeutics Inc
DTSS Datasea Inc
MOXC Moxian Inc
EDRY EuroDry Ltd
Go

Health Care : Biotechnology | Small Cap Blend
Based in Israel
Company profile

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.

Closing Price
$5.33
Day's Change
-0.13 (-2.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.54
Day's Low
5.33
Volume
(Above Average)
Volume:
71,746

10-day average volume:
63,874
71,746

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.23x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2020
Current Month
20.4K
Previous Month
10.8K
Percent of Float
0.27%
Days to Cover
0.2765 Days

Share Information

ENLV is in a share class of common stock
Float
7.5M
Shares Outstanding
13.4M
Institutions Holding Shares
--
--

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Shai A. NovikChmn.
  • Oren HershkovitzCEO
  • Dror Mevorach
  • Shachar ShlosbergerCFO
  • Odelia Ben-ShitritOther

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.